

B79

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 721 611 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
15.11.2006 Bulletin 2006/46

(51) Int Cl.:  
**A61K 31/70** (2006.01) **A61K 31/18** (2006.01)

(21) Application number: 05103260.5

(22) Date of filing: 21.04.2005

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR**  
Designated Extension States:  
**AL BA HR LV MK YU**

(71) Applicant: **N.V. Nutricia**  
**2712 HM Zoetermeer (NL)**

(72) Inventors:  
• **Garssen, Johan**  
**3433 DA Nieuwegein (NL)**

• **Van Tol, Eric Alexander Franciscus**  
**6824 MZ Arnhem (NL)**  
• **Sijben, Johannes Wilhelmus Christina**  
**6701 BA Wageningen (NL)**  
• **Verlaan, George**  
**6708 SB Wageningen (NL)**

(74) Representative: **van Westenbrugge, Andries**  
**Nederlandsch Octrooibureau**  
**Postbus 29720**  
**2502 LS Den Haag (NL)**

(54) **Nutritional supplement with oligosaccharides for a category of HIV patients**

(57) The present invention relates to a nutritional product for HIV patients that are not on Highly Active Antiretroviral Therapy. More specifically the invention relates to a nutritional composition comprising oligosac-

charides. This invention also relates to the manufacture of a nutritional supplement for use in HIV patients.

EP 1 721 611 A1

## EP 1 721 611 A1

## Description

## FIELD OF THE INVENTION

5 [0001] The present invention relates to a nutritional product for HIV patients. More specifically the invention relates to a nutritional composition that provides carefully selected nutritional ingredients specifically supporting HIV patients with nutritionally related symptoms. This invention also relates to the manufacture of a nutritional supplement for use in HIV patients.

## 10 BACKGROUND OF THE INVENTION

[0002] Infections with the human immunodeficiency virus (HIV) and the development of acquired immunodeficiency syndrome (AIDS) have had a significant impact on domestic and global health, social, political, and economic outcomes. Worldwide, the number of HIV-1 infected persons exceeds 40 million, the majority of whom live in Asia, sub-Saharan Africa and South America. Despite all the therapeutic advantages achieved during the last decade, including the development of highly active antiretroviral therapy ("HAART"), once an individual has become infected, eradication of the virus still remains impossible.

15 [0003] The importance of nutritional support of HIV infected persons is recognized nowadays. Infected patients may have increased needs for basal energy, proteins, and micronutrients due to the metabolic stress they experience. This stress, coupled with the anorexia and malabsorption associated with the disease, promotes malnutrition. Malnutrition generally affects e.g. the immune-competence, (work) performance and cognition. Providing extra nutrition helps these patients to improve their general nutritional status.

20 [0004] Currently several products are on the market for nutritional support of HIV patients. Different commercial suppliers have several clinical nutrition products on the market, which are listed below.

25 1. Advera, Ross Abbott

[0005] Caloric Distribution:

30 Protein: 18.7% (Soy protein hydrolysate, Sodium Caseinate)  
Carbohydrate: 65.5% (maltodextrin, sucrose, soy fiber)  
Fat: 15.8% (Canola, MCT, Refined, deodorized sardine oil 1.5 e%)  
Caloric Density: 1.28 kcal/mL

35 2. Resource, Novartis

[0006] Caloric Distribution:

40 Protein: 14% (Sodium and Calcium Caseinates, Soy Protein Isolate)  
Carbohydrate: 64% (Corn Syrup, Sugar)  
Fat: 22% (High Oleic Sunflower Oil, Corn Oil)  
Caloric Density: 1.06 kcal/mL

45 3. Benecalorie, Novartis

[0007] Caloric Distribution:

50 Protein: 9% (Calcium Caseinate)  
Carbohydrate: 0%  
Fat: 91 % (High Oleic Sunflower Oil, Mono and Diglycerides)  
Caloric Density: 7 kcal/mL

4. Boost, Mead Johnson now product sold by Novartis

55 [0008] Caloric Distribution:

Protein: 24% (milk protein concentrate, Ca & Na caseinates)  
Carbohydrate: 55% (corn syrup solids, sugar)

## EP 1 721 611 A1

Fat: 21% (canola, high oleic sunflower and corn oils)  
Caloric Density: 1.01 kcal/mL

5 [0009] However, despite the availability of products which support the general nutritional requirements of HIV infected patients, there are no nutritional products available which do not only improve the nutritional status but which additionally significantly reduce or prevent specific HIV infection related symptoms, in particular immune dysfunction, and optionally also intestinal dysfunction and/or glutathione status of the subjects and/or the spread of HIV.

## SUMMARY OF THE INVENTION

10 [0010] It was surprisingly found that compositions comprising oligosaccharides significantly reduce symptoms associated with HIV-infection related immune dysfunction in a group of subjects which do not yet require HAART therapy, but which already suffer from immune dysfunction (an impaired immune system observed concomitantly with the reduction of CD4+ cells in the blood). This pre-clinical target group of HIV patients benefiting from the present compositions can be defined by the CD4+ blood cells counts.

15 Thus, in one embodiment the present invention relates to the use of oligosaccharides, and optionally cysteine and/or source of cysteine, in the manufacture of a composition for use in a method for the treatment and/or prevention of HIV or AIDS, said method comprising administering to a mammal a composition comprising a therapeutically effective amount of oligosaccharide, and optionally cysteine and/or source of cysteine. In another embodiment the compositions further  
20 comprise one or more polyunsaturated fatty acids (PUFAs) and/or one or more biologically active compounds, in particular milk-derived compounds.

[0011] The present invention provides complete nutritional supplements suitable for the nutritional treatment of HIV patients having a CD4+ cell count of 700 cells/ $\mu$ L or below, but which do not yet require HAART therapy. The nutritional supplements of the present invention comprise at least oligosaccharides in a therapeutically effective amount for components supporting the subject's immune function. Optionally, the composition further comprises a component which supports the subject's gut function and/or glutathione status. It was surprisingly found that by using oligosaccharides as nutritional ingredients, immune dysfunction related symptoms of the HIV infection (i.e. infection related symptoms) can be prevented and/or significantly reduced. An even better effect was found when additionally other disease related symptoms, such as gut dysfunction and/or glutathione status were targeted at the same time.

30 [0012] A healthy gut and healthy gut flora are intricately linked to healthy immune function. Potential immune modulating effects by specific fibers/oligosaccharides may be the indirect result of the influence on the gut flora composition (immune effects of bifidobacteria and lactobacilli types have been documented) and/or function (fermentation of fibers produces compounds such as short chain fatty acids that influence general and immunological function of gut cells). Surprisingly the inventors found that the DC-SIGN molecule of dendritic cells can be blocked by certain oligosaccharides. As the blockage of this molecule can potentially prevent the transmission of HIV, the use of these oligosaccharides for blocking the DC-SIGN receptor and for the manufacture of compositions for the prophylaxis and/or treatment of DC-SIGN mediated diseases (in particular HIV and AIDS) is provided in one embodiment of the invention.

## DETAILED DESCRIPTION

General definitions

45 [0013] "Oligosaccharides" refers to carbohydrate chains of monosaccharide units with a chain length of between 1 and 5000, more preferably between 2 and 250, more preferably between 2 and 50, most preferably between 2 and 10. "Degree of polymerization" or "DP" refers to the total number of saccharide units in an oligosaccharide chain. The "average DP" refers to the average DP of oligosaccharide chains in a composition, without taking possible mono- or disaccharides into account (which are preferably removed if present). The average DP of a composition is used to distinguish between compositions. Preferably the average degree of polymerization of oligosaccharide mixtures is between 2 and 100, more preferably between 3 and 250, e.g. between 3 and 50.

50 "Co-administration" of two or more substances refers to the administration of these substances to one individual, either in one composition or in separate compositions (kit of parts; as a combined composition) which are administered at the same time (simultaneously) or within a short time-span (separate or sequential use, e.g. within minutes or hours).

The term "comprising" is to be interpreted as specifying the presence of the stated parts, steps or components, but does not exclude the presence of one or more additional parts, steps or components.

55 "Percentage" or "average" generally refers to percentages of averages by weight, unless otherwise specified or unless it is clear that another basis is meant.

"GOS" or "galactooligosaccharides", or "trans-galactooligosaccharides" or "TOS" refers to oligosaccharides composed of galactose units.

## EP 1 721 611 A1

"Treatment and/or prevention of HIV" refers to the significant reduction or prevention of one or more of HIV infection related symptoms/dysfunctions, in particular immune dysfunction, and optionally also intestinal dysfunction and/or low glutathione status. In one embodiment treatment or prevention of HIV refers to a significant reduction in (or a complete prevention of) the spread of HIV due to blockage of the DC-SIGN receptor, as will be clear from the context.

"Target group" or "patient group" refers to subjects which have less than about 700 CD4+ cells per microliter blood but which do not yet require and do not yet receive HAART therapy (as this therapy can lead to other symptoms). In particular these patients have between above about 200 or above about 300 or 350 CD4+ cells per microliter blood. Thus HIV infected patients having a CD4+ cell count in the ranges of about 200-700 and various ranges falling within this range, e.g. 250-700, 300-700, 350-700, 400-700, 500-700, 600-700, 200-500, 200-600, 300-500, 300-600, etc. are part of the target group as long as they do not need and do not receive HAART treatment.

A "significant reduction or prevention" refers to a reduction of the symptom (or spread of HIV) by at least 5%, 10%, 15%, 30%, 50% or even 100% compared to control subjects, not being administered the compositions according to the invention. The symptoms can be measured as known in the art, e.g. immune dysfunction can be assessed by measuring CD4+ cell counts. Blockage of the DC-SIGN receptor can be determined as in Example 1.

**[0014]** The object of the present invention is to provide nutritional compositions suitable for treating HIV patients in order to improve their nutritional status and at least one HIV related symptom, in particular immune dysfunction and optionally also intestinal dysfunction and/or glutathione status. The compositions according to the invention are particularly useful for patients with a CD4+ T cell count that is below the critical level of around 700 cells/ $\mu$ l blood, when generally HAART therapy is not yet needed (and is not given), but when patients do already develop or experience one or more of the immune-, intestinal- and/or glutathione related dysfunctions.

**[0015]** Thus, the present compositions are suitable for prevention and/or treatment of one or more of HIV infection related dysfunctions, in particular:

1. immune dysfunction, i.e. a decrease in CD4+ T cell count leading to impaired immune function; and optionally also:
2. intestinal dysfunction, i.e. intestinal problems, specifically HIV induced malabsorption and diarrhea; and/or
3. low glutathione status, specifically low glutathione levels in the blood and intracellularly in the T cells.

**[0016]** In a preferred embodiment the compositions are suitable for treatment or prevention of at least immune dysfunction and optionally low glutathione status. These compositions comprise suitable amounts of oligosaccharides and optionally cysteine and/or source of cysteine. In another embodiment the compositions further comprise suitable amounts of one or more PUFA(s) and/or one or more biologically active compounds and are suitable for treatment or prevention of all three of the above dysfunctions.

**[0017]** Since CD4+ T-lymphocytes are infected and destroyed by HIV, the progression of HIV can be routinely and regularly monitored by measuring the CD4+ T-lymphocyte count in the circulation. The initial period after infection with HIV, which can last from three to more than ten years, is characterized by a slow but gradual decline in total CD4+ T-cell counts, with no apparent symptoms of decreased resistance to infections. The first signs of infectious complications usually occur when CD4+ T cell counts are below 700 cells/ $\mu$ l blood. At this point, the HIV seropositive individual may experience respiratory (coughs, colds, flu) and/or gastrointestinal (bowel discomfort, diarrhea) symptoms. These symptoms are still relatively mild and may be considered sub clinical; although bothersome to the individual, they are usually not sufficiently severe to cause hospitalization or the initiation of highly active antiretroviral treatment (HAART). In one embodiment it was surprisingly found that the administration of oligosaccharides significantly reduces or prevents the development of pre clinical symptoms associated with a reduced functioning (or weakening) of the immune system, such as increased frequency and/or severity of infections by viruses, microorganisms etc.

**[0018]** One of the cell types first encountered by human immunodeficiency virus type 1 (HIV-1) following sexual transmission is dendritic cells (DC). DC capture HIV-1 through C-type lectin receptors, of which the best-studied example is DC-SIGN, which mediates HIV-1 internalization. DC can keep the virus infectious for several days and are able to transmit HIV-1 to CD4(+) T cells. As is described in Example 1, the present inventors surprisingly found that oligosaccharides bind to DC-SIGN.

#### Compositions and uses according to the invention

**[0019]** The compositions according to the invention are suitable for the treatment and/or prevention of HIV and/or AIDS in a mammalian subject, especially in members of the target group, as defined. The subjects are preferably human subjects infected with HIV, and comprising a CD4+ cell count of about 700 cell per  $\mu$ l blood, or less, more preferably between about 200 and 700 cells per  $\mu$ l, e.g. between about 200 and 500 cells or between about 200 and 600 or 500 and 700 cells per  $\mu$ l blood. Preferably the subjects have a CD4+ cell count of 700 or less but are not on highly active antiretroviral therapy (HAART),

In one embodiment the nutritional compositions are preferably food supplements and comprise a therapeutically effective

## EP 1 721 611 A1

amount of one or more oligosaccharides and optionally cysteine and/or source of cysteine.

### Oligosaccharides

[0020] The compositions according to the invention comprise a therapeutically effective amount of oligosaccharides, preferably acid oligosaccharides and/or neutral oligosaccharides as described below.


[0021] Acid oligosaccharides comprise at least one acidic group while neutral oligosaccharides do not have such an acidic group. Dietary fibers have been extensively investigated for their health-beneficial effects. Some fibers are insoluble and non-fermentable and pass unchanged through the gut. Other fiber types may serve as prebiotics, i.e., they are used by gut bacteria and stimulate their growth. Thus, fibers such as inulin or oligosaccharides such as galactooligosaccharides (GOS) and fructo-oligosaccharides (FOS) have been documented to stimulate growth of bifidobacteria and lactic acid bacteria, which are important for a healthy gut flora.

### Acid oligosaccharides

[0022] The term "acid oligosaccharide(s)" refers to oligosaccharides comprising at least one acidic group selected from the group consisting of N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group. In one embodiment the acid oligosaccharide preferably is a polyhexose. Preferably, at least one of the aforementioned acid groups is situated at the terminal hexose unit of the acid oligosaccharide. Preferably the acid oligosaccharide has the structure as depicted in Fig.1, wherein the terminal hexose (left) preferably comprises a double bond. Preferably the acid oligosaccharide contains a carboxylic acid at the terminal hexose unit, wherein said carboxylic acid group may be free or esterified. Methods for the manufacture of esterified pectin hydrolysates that can be suitably used in the present method and composition are provided in WO 01/60378 and/or WO 02/42484, which are hereby incorporated by reference.

The hexose units other than the terminal hexose unit(s) are preferably uronic acid units, even more preferably galacturonic acid units. The carboxylic acid groups on these units may be free or (partly) esterified, and preferably at least 10% is methylated (see below).

[0023] Fig.1. Polymeric acid oligosaccharide



wherein:

R is preferably selected from the group consisting of hydrogen, hydroxy or acid group, preferably hydroxy; and at least one selected from the group consisting of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> represents N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group, and the remaining of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> representing hydroxy and/or hydrogen. Preferably one selected from the group consisting of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> represents N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group or phosphoric acid group, and the remaining represent hydroxy and/or hydrogen. Even more preferably one selected from the group consisting of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> represents free or esterified carboxylic acid and the remaining of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> representing hydroxy and/or hydrogen; and n is an integer and refers to a number of hexose units (see also Degree of Polymerisation, below), which may be any hexose unit. Suitably n is an integer between 1-5000. Preferably the hexose unit(s) is an uronic acid unit. Most preferably R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> represent hydroxy, R<sub>4</sub> represent hydrogen, R<sub>5</sub> represents carboxylic acid, n is any number between 1 and 250, preferably between 1 and 10 and the hexose unit is galacturonic acid.

[0024] The detection, measurement and analysis of the acid oligosaccharides as used in the present method are given


## EP 1 721 611 A1

in applicant's earlier patent application relating to acid oligosaccharides, i.e. WO 01/60378, which is hereby incorporated by reference.

[0025] Preferably, the acid oligosaccharide has one, preferably two, terminal uronic acid units, which may be free or esterified. Preferably the terminal uronic acid unit is selected from the group consisting of galacturonic acid, glucuronic acid, guluronic acid, iduronic acid, mannuronic acid, riburonic acid and alduronic acid. These units may be free or esterified. In one embodiment, the terminal hexose unit has a double bond, which is preferably situated between the C<sub>4</sub> and C<sub>5</sub> position of the terminal hexose unit. Preferably one of the terminal hexose units comprises the double bond. The terminal hexose (e.g. uronic acid) preferably has a structure according to Fig.2.

Fig. 2: Preferred terminal hexose acid group

[0026]



wherein;

R is preferably selected from the group consisting of hydrogen, hydroxy or acid group, preferably hydroxy (see above); and

at least one selected from the group consisting of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> represents N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group, and the remaining of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> representing hydroxy and/or hydrogen. Preferably one selected from the group consisting of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and

R<sub>5</sub> represents N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group, and the remaining of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> represent hydroxy and/or hydrogen. Even more preferably one selected from the group consisting of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> represents free or esterified carboxylic acid and the remaining of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> represent hydroxy and/or hydrogen; and n is an integer and refers to a number of hexose units (see also Degree of Polymerisation, below), which may be any hexose unit. Suitably n is an integer between 1-5000 representing the number of hexose units, said hexose units preferably being uronic acid, even more preferably being galacturonic acid units. The carboxylic acid groups on these units may be free or (partly) esterified, and are preferably at least partly methylated.

Most preferably, R<sub>2</sub> and R<sub>3</sub> represent hydroxy, R<sub>4</sub> represent hydrogen and R<sub>5</sub> represents free or esterified carboxylic acid.

[0027] In one embodiment the compositions comprise a single type of acid oligosaccharide (having a uniform degree of polymerization), while in another embodiment the compositions comprise a mixture of acid oligosaccharides which have different Degrees of Polymerization (DP) and/or comprise both unsaturated and saturated terminal hexose unit. Preferably at least 5%, more preferably at least 10%, even more preferably at least 25% of the terminal hexose units of the acid oligosaccharide unsaturated hexose unit (see e.g. Fig.2). As each individual acid oligosaccharide preferably comprises only one unsaturated terminal hexose unit, preferably no more than 50% of the terminal hexose units is an unsaturated hexose unit (i.e. comprises a double bond).

A mixture of acid oligosaccharides preferably contains between 2 and 50% unsaturated hexose units based on the total amount of hexose units, preferably between 10 and 40%.

[0028] The acid oligosaccharide as used in the present method has a degree of polymerisation (DP) between 1 and 5000, preferably between 1 and 1000, more preferably between 2 and 250, even more preferably between 2 and 50, most preferably between 2 and 10. If a mixture of acid oligosaccharides with different degrees of polymerisation is used,

## EP 1 721 611 A1

the average DP of the acid oligosaccharide mixture is preferably between 2 and 1000, more preferably between 3 and 250, even more preferably between 3 and 50. See also Fig.1, wherein the sum of "n" and the terminal unit (i.e. n+1) represents the degree of polymerisation. It was found that a lower DP of the oligosaccharides improves the palatability and results in a reduced viscosity product if the acid oligosaccharide is administered in liquid form. The acid oligosaccharide may be a homogeneous or heterogeneous carbohydrate.

[0029] The acid oligosaccharides used in the invention are preferably prepared from pectin, pectate, alginate, chondroitine, hyaluronic acids, heparine, heparane, bacterial carbohydrates, sialoglycans, fucoidan, fucooligosaccharides or carrageenan, preferably from pectin and/or alginate. The acid oligosaccharides may be prepared by the methods described in WO 01/60378, e.g. chemical or enzymatic hydrolysis or partial hydrolysis, see page 8 and 9, which is hereby incorporated by reference.

[0030] Alginates are linear unbranched polymers containing  $\beta$ -(1  $\rightarrow$  4)-linked D-mannuronic acid and  $\alpha$ -(1  $\rightarrow$  4)-linked L-guluronic acid residues with a wide range of average molecular weights (100 - 100000 residues). Suitable sources of alginate include seaweeds and bacterial alginates.

[0031] Pectin is divided into two main categories: high methoxylated pectin, which is characterised by a degree of methoxylation above 50% and low methoxylated pectin having a degree of methoxylation below 50%. As used herein, "degree of methoxylation" (also referred to as DE or "degree of esterification") is intended to mean the extent to which free carboxylic acid groups contained in the polygalacturonic acid chain have been esterified (e.g. by methylation). The present acid oligosaccharide is preferably prepared from high methoxylated pectin.

[0032] The acid oligosaccharides are preferably characterised by a degree of methoxylation above 20%, preferably above 50 % even more preferably above 70%. Preferably the acid oligosaccharides have a degree of methylation above 20%, preferably above 50 % even more preferably above 70%.

[0033] The acid oligosaccharide(s) is/are preferably administered in an amount of between about 10 mg and 100 gram per day, preferably between about 100 mg and 50 grams per day, even more preferably between about 0.5 and 20 gram per day.

#### *Neutral oligosaccharides*

[0034] As mentioned above, the compositions may also comprise one or more neutral oligosaccharides, either instead of or in addition to one or more acid oligosaccharides. One or more neutral oligosaccharides are selected from the group consisting of cellobiose, cellodextrins, B-cyclodextrins, indigestible dextrin, gentiooligosaccharides, glucooligosaccharides, isomaltoligosaccharides, isomaltose, isomaltotriose, panose, leucrose, palatinose, theandrose, D-agatose, D-lyxo-hexulose, lactosucrose,  $\alpha$ -galactooligosaccharides,  $\beta$ -galactooligosaccharides, transgalactooligosaccharides, lactulose, 4'-galatosyllactose, synthetic galactooligosaccharide, fructans - Levan-type, fructans - Inulin-type, 1 f- $\beta$ -fructofuranosylmystose, lacto N-tetraose, lacto N-neotetraose, xylooligosaccharide, lafmoose, lactosucrose and arabinooligosaccharides.

[0035] Preferably the neutral oligosaccharide is selected from the group consisting of galactooligosaccharide, fructooligosaccharide, transgalactooligosaccharide, xylooligosaccharide, lactosucrose and arabinooligosaccharides. Even more preferably the neutral oligosaccharide is selected from the group consisting of galactooligosaccharide, fructooligosaccharide and transgalactooligosaccharide..

[0036] Preferably the composition comprises two chemically distinct neutral oligosaccharides, one selected from the group consisting of galactose based neutral oligosaccharide and one selected from the group of fructose and/or glucose based oligosaccharide.

[0037] More preferably the composition comprises fructooligosaccharide and at least one oligosaccharide selected from transgalactooligosaccharide and galactooligosaccharide.

[0038] Preferred daily amounts of neutral oligosaccharides are between about 10 mg and 100 gram per day, preferably between about 100 mg and 50 grams per day, even more preferably between about 0.5 and 20 gram per day.

[0039] Preferably a composition comprising neutral and acid oligosaccharides is used wherein at least 15% of the total oligosaccharides comprise of acid oligosaccharides more preferably between 10 and 90% and most preferably between 25 and 75%. Preferably a composition is used wherein at least 25% of the oligosaccharides are acid oligosaccharides comprising at least one terminal uronic acid unit.

#### Cysteine or source of cysteine

[0040] The compositions provided optionally further comprise in addition to one or more oligosaccharides as described above a suitable amount of cysteine and/or source of cysteine. The phrase "source of cysteine" refers herein to all compounds that contain a biologically available cysteine, in any form, and is calculated as the amount of cysteine amino acid that is present in a compound, or can be derived from a compound in the body after ingestion, on a molar basis.

[0041] Hereinbelow "cysteine equivalent" refers to an amount of cysteine as such or to an amount of cysteine that is

## EP 1 721 611 A1

present in a source of cysteine. For example 100 mg NAC (N-acetylcysteine; MW= 163.2) is equivalent to 74 mg cysteine (MW 121.15). Thus 100 mg NAC is 74 mg cysteine equivalent. Similarly this can be applied to proteins or peptides. When a peptide (MW = xDalton) contains 3 cysteine amino acids (3yDalton), then 100 mg of this peptide is equivalent to  $100 \times 3y/x$  mg cysteine. Thus 100mg of this peptide is  $300y/x$  mg cysteine equivalent.

[0042] Suitable sources of cysteine according to the invention are, for example, proteins in denatured and/or undenatured form such as milk proteins e.g. whey or casein proteins. Egg proteins are rich in cysteine and are therefore also suitable. Plant proteins such as pea, potato, soy and rice can also be used to provide cysteine. Also hydrolysates of these protein sources can be used or fractions enriched for cysteine rich proteins or peptides (e.g. as described in EP1201137). Furthermore, synthetic cysteine equivalents, e.g. derivatives of cysteine, such as cysteine, cysteine salts, N-acetylcysteine and/or diacetylcysteine can be used.

[0043] The HIV infected target patients are suitably administered a daily dose of at least about 100 mg cysteine equivalent, preferably at least about 200, 400, or 600 mg cysteine equivalent per day, more preferably at least about 1000 mg cysteine equivalent per day. It is understood that a daily dosage can be subdivided into 2, 3 or more dosage units taken several times a day.

[0044] In yet another embodiment the compositions according to the invention optionally further comprise one or more compounds that stimulate glutathione levels. e.g. lipoic acid, pyruvate, oxaloacetate, oxaloaspartate, are capable in stimulating glutathione levels. Such glutathione level stimulating compounds may be used in addition to cysteine but also instead of cysteine.

[0045] In another embodiment the compositions comprising one or more oligosaccharides, (and optionally cysteine and/or source of cysteine) further optionally comprise one or more PUFAs and/or one or more biologically active compounds, such as compounds found in milk and/or probiotic micro-organisms.

#### Probiotic micro-organism

[0046] Probiotic micro-organism means a micro-organism which beneficially affects a HIV patient by improving its intestinal microbial balance (Fuller, R. J. Applied Bacteriology, 1989;66:365-378). The probiotic micro-organism may be selected from one or more micro-organisms suitable for human consumption and which is able to improve the microbial balance in the intestine. Preferably, the present composition contains  $10^4$  to  $10^{12}$ , more preferably from  $10^5$  to  $10^{11}$ , most preferably from  $10^7$  to  $5 \times 10^{10}$  colony forming units (cfu) of probiotic bacteria per gram uronic acid oligosaccharide with a DP between 2 and 100. The present composition preferably contains  $10^2$  to  $10^{13}$  colony forming units (cfu) of probiotic bacteria per gram dry weight of the present composition, preferably  $10^4$  to  $10^{12}$ , more preferably  $10^5$  to  $10^{10}$ , most preferably from  $10^5$  to  $1 \times 10^9$  cfu. The dosage of probiotic bacteria according to the present invention is preferably between  $10^2$  to  $10^{13}$ , more preferably from  $10^5$  to  $10^{11}$ , most preferably from  $10^8$  to  $5 \times 10^{10}$  colony forming units (cfu) per day. Preferably live or viable bacteria are used, but dead bacteria or bacterial fragments may also be used.

[0047] Thus, in one embodiment the present composition optionally comprises bacteria of the genus *Lactobacillus* and/or *Bifidobacterium*. Preferably the composition comprises a *Bifidobacterium* selected from the group consisting of *B. longum*, *B. breve* and *B. bifidum* and/or a *Lactobacillus* selected from the group consisting of *L. casei*, *L. paracasei*, *L. rhamnosus*, *L. acidophilus* and *L. plantarum*. Most preferably the present composition comprises *Bifidobacterium breve* and/or *Lactobacillus paracasei*.

[0048] *Bifidobacterium breve* is a Gram-positive, anaerobic, rod-shaped bacterium. The present *B. breve* preferably has at least 95 % nucleic acid sequence identity of the 16 S rRNA sequence when compared to the type strain of *B. breve* ATCC 15700, more preferably at least 97%, 98%, 99% or more sequence identity as defined in Stackebrandt & Goebel, 1994, Int. J. Syst. Bacteriol. 44:846-849. Nucleic acid sequence identity is calculated for two nucleotide sequences, when optimally aligned, using the programs GAP or BESTFIT using default parameters. The GAP default parameters are used, with a gap creation penalty = 50 (nucleotides) / 8 (proteins) and gap extension penalty = 3 (nucleotides) / 2 (proteins). For nucleotides the default scoring matrix used is nwsgapdna (Henikoff & Henikoff, 1992, PNAS 89, 915-919). It is clear than when RNA sequences are said to be essentially similar or have a certain degree of sequence identity with DNA sequences, thymine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence. Sequence alignments and scores for percentage sequence identity may be determined using computer programs, such as the GCG Wisconsin Package, Version 10.3, available from Accelrys Inc., 9685 Scranton Road, San Diego, CA 92121-3752, USA or EMBOSWin v. 2.10.0.

[0049] The *Bifidobacterium* used in the present invention preferably gives a signal with the 5' nuclease assay method as described in co-pending international patent application PCT/NL2004/000748 and european patent application 05075486.0 of the present applicant. According to a preferred embodiment, the present composition contains at least one *B. breve* selected from the group consisting of *B. breve* Bb-03 (Rhodia), *B. breve* M16-V (Morinaga), *B. breve* R0070 (Institute Rosell, Lallemand), DSM 20091, and LMG 11613. Most preferably, the *B. breve* is *B. breve* M-16V (Morinaga). In a preferred embodiment the present composition comprises *Lactobacillus paracasei*. Preferably the present *L. paracasei* strain has at least 95%, more preferably at least 97%, 98%, 99% or more nucleic acid sequence identity of the



## EP 1 721 611 A1

16S rRNA sequence when compared to the type strain of *L. paracasei* ATCC 25032 as defined above. The *Lactobacillus* used in the present invention preferably gives a signal with the 5' nuclease assay method as described in co-pending european patent application 05075486.0 of the present applicant. According to a preferred embodiment, the present composition contains at least a *L. paracasei* selected from the group consisting of *L. paracasei* F19 (Arla, Sweden), *L. paracasei* LAFTI L26 (DSM Food Specialties, the Netherlands) and *L. paracasei* CRL 431 (Chr. Hansen, Denmark), LMG 12165 and LMG 11407.

Polyunsaturated fatty acids

[0050] The present inventors found that eicosapentaenoic acid (EPA, n-3) and gamma linolenic acid (GLA, n-6) effectively reduce inflammatory mediated intestinal tight junction permeability. Hence a composition, the compositions suitable for treatment of the target patients may further comprise one or more PUFAs for improving intestinal barrier integrity. In one embodiment the compositions comprise (in addition to oligosaccharides) EPA and/or GLA. Based on the biochemical pathways it can be hypothesized that also other combinations of fatty acids are also effective. Thus, compositions comprising one or more other PUFAs or mixtures thereof, are also provided. For example a mixture of any of EPA, docosahexaenoic acid (DHA, n-3), dihomo-gamma linolenic acid (DGLA, C20:3n-6), stearidonic acid (STA, C18:4n-4), alpha linolenic acid (ALA, C18:3n-3), (docosapentaenoic acid (DPA, C22:5n-3), eicosatetranoic acid (C20:4n-3) and/or arachidonic acid (AA, n-6) may be used.

[0051] Suitably a relatively high daily dose of the polyunsaturated fatty acids is used. In one embodiment at least about 25 en%, preferably at least about 30 en%, more preferably at least about 35 en% of a fat blend comprising n-3 and/or n-6 fatty acids is used (en% is short for energy percentage and represents the relative amount each constituent contributes to the total caloric value of the preparation). Preferred daily amounts are at least 1 gram PUFA, more preferably between 1-50 gram PUFA, more preferably between 5 and 25 gram PUFA and most preferred is an amount between 7.5 and 15 gram PUFA.

[0052] An optimal fat blend may e.g. comprise 40% borage oil and 60% fish oil. The n-3/n-6 fatty acid ratio is then between 1-2 and the weight percentage of n-3 is between 20-40, and of n-6 is between 15-35 of total fatty acid content. Borage oil can partly or completely be replaced by evening primrose oil.

[0053] Therefore preferred daily amounts are at least 0.1 gram EPA and 0.05 gram GLA, more preferably between 0.1 and 5 gram EPA and between 0.05 and 2.5 gram GLA, more preferably between 0.5 and 2.5 gram EPA and between 0.25 and 1.25 gram GLA and most preferred is an amount between 0.75 and 1.5 gram EPA and between 0.37 and 0.75 gram GLA.

Biologically active ingredients

[0054] The compositions according to the invention may optionally further comprise one or more biologically active molecules, preferably components found naturally in milk. These include growth factors, immunoglobulins, and other milk components or milk derived components.

## A. Growth factors

[0055] It has been found that milk growth factors are beneficial for gut health. Transforming growth factor-beta, insulin like growth factor and keratinocyte growth factors are the most important examples of milk growth factors. Therefore, in one embodiment the compositions further comprise one or more growth factors, e.g. about 1-500 µg growth factors per day.

## B. Immunoglobulins

[0056] Immunoglobulins have been shown to protect against intestinal infections and the compositions according to the invention suitably comprise a daily dose from 0,1 to 10g immunoglobulins.

## C. Other ingredients

[0057] Other bioactive ingredients obtainable from milk e.g. nucleotides, fatty acids, oligosaccharides were also found to have a beneficial effect on the gut barrier function and may therefore be suitably used in the manufacture of the compositions.

## EP 1 721 611 A1

## D. Colostrum

[0058] In one embodiment the compositions comprise Colostrum. Colostrum is the pre-milk fluid secreted by the mammary glands of mammalian mothers after giving birth, in particular cows after calving. Colostrum contains many biologically active milk ingredients and is therefore an excellent source of biologically active molecules. Colostrum, being a protein source, has the additional advantage of providing cysteine. For having beneficial effects in HIV patients at least about 5 gram colostrum are provided on a daily basis, preferably at least about 10 gram, more preferably at least about 20 g per day or more.

[0059] Extracts from milk proteins, such as a whey growth factor extract as described in EP0545946 or a casein extract as described in WO02083164, immunoglobulin concentrates, lactoferrin or other concentrated whey fractions can also be used to improve the gut barrier function of HIV patients.

[0060] It is understood that the biologically active molecules or components may be obtained using a range of methods. Many are commercially available, or can be made synthetically, by recombinant DNA technology or they can be (partially) purified or extracted from natural sources such as milk. Also mixtures of any of the biologically active molecules or components comprising these molecules may be used.

Compositions suitable for blocking DC-sign receptors

[0061] In another embodiment compositions suitable for the treatment and/or prevention of DC-sign mediated diseases, such as HIV or AIDS, are provided. Such compositions comprise a suitable amount of oligosaccharides, especially acid oligosaccharides as described hereinabove and in Example 1. Preferred are oligosaccharides which have a IC<sub>50</sub> value of about 1000, 600, 400, more preferably 200 µg/ml or less, such as 150, 100, 50, 25 µg/ml or less. The IC<sub>50</sub> value can be determined using methods known in the art (see Examples 1).

[0062] These compositions may additionally further comprise cysteine and/or source of cysteine, PUFAs, probiotics, etc., as described elsewhere herein. The oligosaccharides may be formulated as a pharmaceutical composition or as a food or food supplement composition (as described herein below for compositions comprising oligosaccharides (and optionally cysteine and/or source of cysteine).

[0063] Guidance regarding pharmaceutical formulations that are suitable for various types of administration can be found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, PA, 17th ed. (1985).

Nutritional compositions and food supplements

[0064] It was found that the oligosaccharides can be advantageously applied in food, such as baby food and clinical food. Such food preferably comprises lipid, protein and carbohydrate and can be administered in a liquid or solid form. The term "liquid food" as used in the present invention includes dry food (e.g. powders) that are accompanied with instructions as to admix said dry food mixture with a suitable liquid (e.g. water). Solid food includes food in the form of a supplement bar with a water activity between 0.2 and 0.4. Water activity can be defined as the ratio of the water vapour pressure of a product to the vapour pressure of pure water at the same temperature. The solid product must meet target water activity otherwise the product will not be shelf stable. Also semi-solid food and food-supplements are provided.

[0065] Hence, the present invention also relates to a nutritional composition which *in addition* (check) to the present oligosaccharides comprises between 5 and 50 en% lipid, between 10 and 60 en% protein, between 15 and 85 en% carbohydrate. In the context of this invention it is to be understood that the oligosaccharides in the compositions of the present invention do not deliver calories and are therefore not included in the en% mentioned herein. All proteins, peptides, amino acids do contribute calories and therefore are included in the en% mentioned herein. In one embodiment the nutritional composition comprises between 15 and 50 en% lipid, between 25 and 60 en% protein and between 15 and 45 en% carbohydrate. In another embodiment the present nutritional composition comprises between 15 and 50 en% lipid, between 35 and 60 en% protein and between 15 and 45 en% carbohydrate.

[0066] Preferably lipids are used that have a high content of EPA or GLA. Fish oil and borage or evening primrose oil are preferred sources of these polyunsaturated fatty acids.

[0067] A source of digestible carbohydrate may be added to the nutritional formula. It preferably provides about 25% to about 40% of the energy of the nutritional composition. Any suitable (source of) carbohydrate may be used, for example sucrose, lactose, glucose, fructose, corn syrup solids, and maltodextrins, and mixtures thereof.

[0068] Preferably vitamins and minerals are present in amounts as required by FSMP regulations.

[0069] Diarrhea is a major problem in many HIV patients that receive liquid foods. It was found that stool problems are reduced by administering the present oligosaccharides in a dry nutritional composition or in liquid nutritional composition which have an osmolality between 50 and 500 mOsm/kg, more preferably between 100 and 400 mOsm/kg.

[0070] In view of the above, the nutritional composition preferably does not deliver excessive calories. Hence, the nutritional composition preferably does not contain more than 500 kcal/daily dose, more preferably between 200 and

## EP 1 721 611 A1

400 kcal/daily dose and more preferably between 250 and 350 kcal/daily dose.

[0071] In accordance with the foregoing, the present invention relates to a nutritional composition comprising:

- a) oligosaccharides, preferably the oligosaccharides comprise at least acid oligosaccharides preferably in such an amount that between 10 mg and 100 gram per day, preferably between about 100 mg and 50 grams per day, even more between about 0.5 and 20 gram is supplied in a daily dose, and optionally
- b) cysteine and/or source of cysteine, preferably wherein at least 0.1 g cysteine equivalent is supplied in a daily dose, and/or optionally
- c) one or more biologically active ingredients (e.g. colostrums and/or probiotics) and/or PUFA (e.g. EPA and/or GLA), preferably wherein at least 1 gram PUFA, more preferably between 1-50 gram PUFA, more preferably between 5 and 25 gram PUFA and even more preferably between 7.5 and 15 gram PUFA is supplied in a daily dose, also preferably at least 0.1 gram EPA and 0.05 gram GLA, more preferably between 0.1 and 5 gram EPA and between 0.05 and 2.5 gram GLA, more preferably between 0.5 and 2.5 gram EPA and between 0.25 and 1.25 gram GLA and even more preferably between 0.75 and 1.5 gram EPA and between 0.37 and 0.75 gram GLA is supplied in a daily dose.

[0072] In one embodiment the nutritional composition comprises between 5 and 50 en% lipid, between 35 and 60 en% protein, between 15 and 60 en% carbohydrate and a therapeutically effective amount of acid and/or neutral oligosaccharides (and optionally cysteine and/or source of cysteine wherein the source of cysteine is selected from the group consisting of NAC, whey, colostrum, egg proteins or mixtures thereof).

[0073] In another embodiment the food composition comprises between 15 and 50 en% lipid, between 35 and 60 en% protein, between 15 and 45 en% carbohydrate and a therapeutically effective amount of acid and/or neutral oligosaccharides (and optionally cysteine or and/or source of cysteine wherein the source of cysteine is selected from the group consisting of NAC, colostrum, egg proteins or combinations thereof).

[0074] The nutritional composition is preferably in the form of or administered as a food supplement. This nutritional composition or food supplement can be advantageously used in a method for treating HIV patients, said method comprising administering said composition or supplement to a mammal, preferably a human infected with HIV and belonging to the target group.

[0075] Also provided is a method for manufacturing a composition for use in the treatment and/or prevention of HIV, said method comprising

- providing a suitable amount of one or more oligosaccharides;
- formulating the above components into a suitable food or food supplement or pharmaceutical composition.

[0076] The following examples illustrate the invention. Unless stated otherwise, the practice of the invention will employ standard conventional methods of molecular biology, pharmacology, immunology, virology, microbiology or biochemistry. Such techniques are described in Sambrook and Russell (2001) Molecular Cloning: A Laboratory Manual, Third Edition, Cold Spring Harbor Laboratory Press, NY, in Volumes 1 and 2 of Ausubel et al. (1994) Current Protocols in Molecular Biology, Current Protocols, USA and Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed. (1985), Microbiology: A Laboratory Manual (6th Edition) by James Cappuccino, Laboratory Methods in Food Microbiology (3rd edition) by W. Harrigan (Author) Academic Press, all incorporated herein by reference.

## EXAMPLES

### Example 1. Blockage of DC-SIGN - Fc binding by acid oligo's and GOS

[0077] Blocking DC-SIGN has been shown to prevent viral translocation from dendritic cells to CD4 T-cells. The inventors surprisingly found that oligosaccharides can block DC-SIGN with different efficacy. Acid oligosaccharides (AOS), like pectin hydrolysate, are the most potent as shown in Table 1. These results show that AOS can prevent binding of Fc fragments to DC-SIGN at the lowest concentration.

TABLE 1. EFFICACY OF DC-sign BINDING BY OLIGOSACCHARIDES

Oligosaccharide	I.C. 50 (µg/ml)
Acid Oligosaccharide (pectin hydrolysate)	200
Galacto oligosaccharides (Trans galacto- oligosaccharides)	600
Fructooligosaccharide (Inuline HP)	>1000

## EP 1 721 611 A1

## Material and methods:

[0078] Oligosaccharide preparations were coated on ELISA plate in serial dilutions. DC-SIGN - Fc binding was measured in an ELISA using anti-DC-SIGN- Fc and was visualized by adding a labeled secondary antibody. OD was measured with a spectrophotometer (Becton Dickinson) after 20 minutes of incubation. Results are depicted as the inhibitory concentration at 50% inhibition.

## Example 2. Composition of a nutritional bar

Raw Material	Code	g/ day	protein	g/ 100g
Colostrum	SR	20.00	15.00	27.38
borage oil (Ropufa 25 n-6)	2000342	4.00	0.00	5.48
EPA-DHA oil (Maruha)	2001292	6.00	0.00	8.21
Galacto-oligosaccharides Elix'or syrup	2001189	15.38	0.00	21.06
Inuline (Raftiline HP)	2001190	0.79	0.00	1.08
Acid Oligos (pectin hydrol.)	SR	8.54	0.11	11.69
N-acetyl-Cysteine	SR	1.83	1.34	2.50
Fructosestrop	JJ	13.20	0.00	18.07
Glycerine	JJ	3.30	0.00	4.52
<b>per day kcal En%</b>				
energy protein	66	26.9		
energy carbohydrates	82	33.4		
energy fat	97	39.7		
	245			

## Example 3. Composition of a nutritional bar

Raw Material	Code	g/ day	protein	carbs	fat	g/ 100g
Colostrum	SR	20.00	15.00	2.10	0.80	21.04
borage olie (Ropufa 25 n-6)	2000342	4.00	0.00	0.00	4.00	4.21
EPA-DHA oil (Maruha)	2001292	6.00	0.00	0.00	6.00	6.31
Galacto-oligosaccharides (Elixer or syrup)	2001189	15.38	0.00	4.78	0.00	16.18
Inuline (Raftiline HP)	2001190	0.79	0.00	0.00	0.00	0.83
Acid Oligos (pectin hydrol.)	SR	8.54	0.11	0.09	0.00	8.98
Egg shell membrane powder		21.09	16.87	0.00	0.00	22.19
Fructosestrop	JJ	15.40	0.00	11.92	0.00	16.20
glycerine	JJ	3.85	0.00	3.83	0.00	4.05
SUM		95.05	31.98	22.72	10.80	100.00
<b>per day kcal En% per 100g kcal</b>						
energy protein	128	40.5	135			
energy carbs	91	28.8	96			
energy fat	97	30.8	102			
SUM	316		332			

## Example 4. Powder composition

Raw Material	Code	g/ day	protein	carbs	fat	g/ 100g
Colostrum	SR	20.00	15.00	2.10	0.80	29.39
borage oil (Ropufa 25 n-6)	2000342	4.00	0.00	0.00	4.00	5.88
EPA-DHA oil (Maruha)	2001292	6.00	0.00	0.00	6.00	8.82
GOS/MD DE2 powder	2001189	14.78	0.00	7.66	0.00	21.72
Inuline (Raftiline HP)	2001190	0.79	0.00	0.00	0.00	1.16

## EP 1 721 611 A1

(continued)

Raw Material	Code	g/ day	protein	carbs	fat	g/ 100g
Acid Oligos (pectin hydrol.)	SR	8.54	0.11	0.09	0.00	12.55
N-acetyl-Cysteine	SR	1.83	1.34	0.00	0.00	2.69
MD DE47	MM	7.00	0.01	6.75	0.02	10.29
MD DE47	MM	5.00	0.01	4.82	0.01	7.35
SSL (emulsifier)	SHS	0.11	0.00	0.00	0.11	0.17
<b>SUM</b>		<b>68.05</b>	<b>16.46</b>	<b>21.41</b>	<b>10.94</b>	<b>100.0</b>
	<b>per day kcal</b>	<b>En%</b>	<b>per 100g kcal</b>			
energy protein	66	26.3	97			
energy carbs	86	34.3	126			
energy fat	98	39.4	145			
<b>SUM</b>	<b>250</b>		<b>367</b>			

**Example 5. Powder composition**

Raw Material	Code	g/ day	protein	carbs	fat	g/ 100g
Colostrum	SR	20.00	15.00	2.10	0.80	19.95
borage oil (Ropufa 25 n-6)	2000342	4.00	0.00	0.00	4.00	3.99
EPA-DHA oil (Maruha)	2001292	6.00	0.00	0.00	6.00	5.98
GOS/MaltoDex	2001189	14.78	0.00	7.66	0.00	14.74
(DE2 powder)						
Inuline (Raftiline HP)	2001190	0.79	0.00	0.00	0.00	0.79
Acid Oligos (pectin hydrol.)	SR	8.54	0.11	0.09	0.00	8.52
alpha-lactalbumin (Davisco)		34.03	31.21	0.17	0.17	33.94
MaltoDex DE47	MM	7.00	0.01	6.75	0.02	6.98
MaltoDex DE47	MM	5.00	0.01	4.82	0.01	4.99
SSL (emulsifier)	SHS	0.11	0.00	0.00	0.11	0.11
<b>SUM</b>		<b>100.25</b>	<b>46.33</b>	<b>21.58</b>	<b>11.11</b>	<b>100.00</b>
	<b>per day kcal</b>	<b>En%</b>	<b>per 100g kcal</b>			
energy protein	185	49.9	185			
energy carbs	86	23.2	86			
energy fat	100	26.9	100			
<b>SUM</b>	<b>372</b>		<b>371</b>			

**Example 6. Liquid nutritional composition**

Raw Material	Code	g/ day	protein	carbs	fat	g/ ltr
borage oil (Ropufa 25 n-6)	2000342	4.00	0.00	0.00	4.00	10.67
EPA-DHA oil (Maruha)	2001292	6.00	0.00	0.00	6.00	16.00
Galacto-oligosacchariden	2001189	15.38	0.00	4.78	0.00	41.01
(Elixer or syrup)						
Inuline (Raftiline HP)	2001190	0.79	0.00	0.00	0.00	2.11
Acid Oligosaccharides	SR	8.54	0.11	0.09	0.00	22.77
(pectin hydrolysate)						
Egg shell membrane powder	SR	21.09	16.87	0.00	0.00	56.24
WPH (cysteine peptide)	SR		0.00	0.00	0.00	0.00
MaltoDextrin (DE47)	MM	18.80	0.02	18.12	0.05	50.13
<b>SUM</b>		<b>74.60</b>	<b>17.00</b>	<b>22.99</b>	<b>10.05</b>	<b>198.93</b>
	<b>per day kcal</b>	<b>En%</b>	<b>per ltr kcal</b>			
energy protein	68	27.2	181			

## EP 1 721 611 A1

(continued)

	per day kcal	En%	per ltr kcal
energy carbs	92	36.7	245
energy fat	90	36.1	241
<b>SUM</b>	<b>250</b>		<b>668</b>

**Example 7. Liquid nutritional composition**


Raw Material	Code	g/ day	protein	carbs	fat	g/ ltr
borage olie Ropufa 25 n-6	2000342	4.00	0.00	0.00	4.00	10.67
Maruha EPA-DHA oil	2001292	6.00	0.00	0.00	6.00	16.00
Galacto-oligosacchariden (Elixer or syrup)	2001189	15.38	0.00	4.78	0.00	41.01
Raftiline HP (Inuline)	2001190	0.79	0.00	0.00	0.00	2.11
AOS (pectin hydrolysate)	SR	8.54	0.11	0.09	0.00	22.77
WPH (cysteine peptide)	SR	24.19	20.83	0.92	0.02	64.51
MD DE47	MM	13.50	0.02	13.01	0.03	36.00
<b>SUM</b>		<b>72.40</b>	<b>20.95</b>	<b>18.80</b>	<b>10.06</b>	<b>193.07</b>

	per day kcal	En%	per ltr kcal
energy protein	84	33.6	223
energy carbs	75	30.1	201
energy fat	91	36.3	241
<b>SUM</b>	<b>250</b>		<b>665</b>

**Claims**

1. Use of one or more oligosaccharides in the manufacture of a composition for use in a method for the treatment and/or prevention of HIV in a human subject having a CD4+ T-lymphocyte cell count between 200 to 700 cells/ $\mu$ l blood and wherein said subject is not being treated by Highly Active Antiretroviral Therapy.
2. Use according to claim 1 or 2, wherein the oligosaccharides are acid oligosaccharides comprising at least one terminal uronic acid unit.
3. Use according to claim 3, wherein the uronic acid unit is selected from the group consisting of galacturonic acid, glucuronic acid, guluronic acid, iduronic acid, mannuronic acid, riburonic acid and alduronic acid.
4. Use according to any of the preceding claims, wherein the terminal hexose unit of the oligosaccharide has the following structure:



wherein;

## EP 1 721 611 A1

R is selected from the group consisting of hydrogen, hydroxy or acid group; and at least one selected from the group consisting of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> represent N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carboxylic acid, sulfuric acid group and phosphoric acid group, and the remaining of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> represent hydroxy and/or hydrogen; and n is an integer from 1-5000.

- 5
- 10
- 15
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55
5. Use according to any of claims 2-4, wherein the terminal uronic acid has the structure as depicted in claim 4 and wherein R represents one selected from the group consisting of hydrogen, hydroxy or acid group ; and one selected from the group consisting of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> represents free or esterified carboxylic acid; and the remaining of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> represent hydroxy and/or hydrogen.
  6. Use according to any one of the preceding claims, wherein the oligosaccharide has a degree of polymerisation between 1 and 250, preferably between 1 and 10.
  7. Use according to any of the preceding claims, wherein the composition further comprises neutral oligosaccharides.
  8. Use according to any of the preceding claims, wherein the composition further comprises cysteine and/or source of cysteine providing at least 100 mg cysteine equivalent in a daily dose.
  9. Use according to claim 8, wherein the source of cysteine is N-Acetyl cysteine, whey, colostrum, egg proteins or a combination thereof.
  10. Use according to claim 9 wherein the whey, colostrums or egg proteins are at least partially hydrolyzed.
  11. Use according to any of the preceding claims, wherein the composition further comprises polyunsaturated fatty acids (PUFA).
  12. Use according to claim 11 wherein the PUFA comprises at least 20% GLA plus EPA, based on the total fatty acid content.

EP 1 721 611 A1



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 05 10 3260  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
E	WO 2005/039597 A (N.V. NUTRICIA; STAHL, BERND; M'RABET, LAURA; VOS, ARJAN, PAUL; GARSSSEN) 6 May 2005 (2005-05-06) * page 8, paragraph 2 - paragraph 3 * * page 10; figure 1 * -----	1-5	C08P37/04 C08P37/06 A61K31/70 A61P31/18
X	US 5 882 648 A (YOSHIHARA ET AL) 16 March 1999 (1999-03-16) * column 1, line 45 - line 50 * -----	1-3,6	
X	NAKANO M ET AL: "Anti-human immunodeficiency virus activity of oligosaccharides from Rooibos tea (Aspalathus linearis) extracts in vitro" LEUKEMIA 1997 UNITED KINGDOM, vol. 11, no. SUPPL. 3, 1997, pages 128-130, XP008052280 ISSN: 0887-6924 * page 129, column 1, paragraph 2 - column 2, paragraph 1 * ----- -/--	1-3,6	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K
<b>INCOMPLETE SEARCH</b>			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
The Hague		14 September 2005	Bonzano, C
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... &amp; : member of the same patent family, corresponding document</p>			

 4  
EPO FORM 1503 03.02 (P4/C07)



EP 1 721 611 A1

European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 05 10 3260

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	PATENT ABSTRACTS OF JAPAN vol. 013, no. 408 (C-634), 8 September 1989 (1989-09-08) & JP 01 149730 A (OSAKA PREFECTURE), 12 June 1989 (1989-06-12) * abstract *	1-3,6	
X	----- DATABASE WPI Section Ch, Week 200261 Derwent Publications Ltd., London, GB; Class A26, AN 2002-567199 XP002344565 & CN 1 343 727 A (null) 10 April 2002 (2002-04-10) * abstract *	1-3,6	
X	----- PATENT ABSTRACTS OF JAPAN vol. 017, no. 119 (C-1034), 12 March 1993 (1993-03-12) & JP 04 300888 A (DAINIPPON INK & CHEM INC), 23 October 1992 (1992-10-23) * abstract *	1-3,6	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	----- US 4 412 946 A (ZALISZ ET AL) 1 November 1983 (1983-11-01) * column 1, line 22 - line 34 *	1-3,6-8	
A	----- US 2004/072791 A1 (KUNZ MARKWART ET AL) 15 April 2004 (2004-04-15) * claims 11,41 *	1-3	
A	----- FR 2 781 673 A (UNIVERSITE DE PICARDIE JULES VERNE) 4 February 2000 (2000-02-04) * page 7, paragraph 4 - paragraph 5 * * page 1, paragraph 1 * ----- -/--		

4  
EPO FORM 1503 (01.02) (P04C10)

EP 1 721 611 A1



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 05 10 3260

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
D,A	WO 01/60378 A (N.V. NUTRICIA; STAHL, BERND; BOEHM, GUENTHER) 23 August 2001 (2001-08-23) * the whole document *		
A	----- JACOBSON MARK A ET AL: "Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy." AIDS (HAGERSTOWN), vol. 17, no. 6, 11 April 2003 (2003-04-11), pages 917-919, XP008052430 ISSN: 0269-9370 * page 917, column 2, paragraph 1 *		TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	KULKARNI S ET AL: "Immunostimulant activity of inulin isolated from Saussurea lappa roots" INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 63, no. 4, July 2001 (2001-07), pages 292-294, XP009029650 ISSN: 0250-474X * page 292, column 1, paragraph 1 *		
	-----		

4

EPO FORM 1503 03.02 (P04C10)

EP 1 721 611 A1

European Patent  
OfficeINCOMPLETE SEARCH  
SHEET CApplication Number  
EP 05 10 3260Claim(s) searched completely:  
-Claim(s) searched incompletely:  
1-12Claim(s) not searched:  
-

Reason for the limitation of the search:

The present claim 1-3, 7-12 relates to an extremely large number of possible compounds. Support and disclosure in the sense of Article 84 and 83 EPC is to be found however for only a very small proportion of the compounds claimed, see examples. The non-compliance with the substantive provisions is to such an extent, that a meaningful search of the whole claimed subject-matter of the claim could not be carried out (Rule 45 EPC and Guidelines B-VIII, 3).

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claims 4-6 may be said to define subject-matter for which protection might legitimately be sought (Article 84 EPC). Moreover, the application provides support within the meaning of Article 84 EPC and disclosure within the meaning of Article 83 EPC for none of such compounds. For these reasons, a meaningful search of the whole claimed subject matter of claims 4,5 could not be carried out (Rule 45 EPC). The extent of the search was consequently limited to those compounds which appear to be supported and a generalisation of their structural formulae, namely pectin hydrolisate.

## EP 1 721 611 A1

ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.

EP 05 10 3260

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-09-2005

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2005039597	A	06-05-2005	NONE	
US 5882648	A	16-03-1999	NONE	
JP 01149730	A	12-06-1989	NONE	
CN 1343727	A	10-04-2002	NONE	
JP 04300888	A	23-10-1992	NONE	
US 4412946	A	01-11-1983	AU 546495 B2	05-09-1985
			AU 7545181 A	25-03-1982
			CA 1151544 A1	09-08-1983
			DE 3162817 D1	26-04-1984
			DK 414981 A	20-03-1982
			EP 0049182 A1	07-04-1982
			ES 8206186 A1	16-11-1982
			FI 812923 A	20-03-1982
			FR 2490496 A1	26-03-1982
			HU 185314 B	28-01-1985
			IE 51590 B1	21-01-1987
			JP 1043760 B	22-09-1989
			JP 1558166 C	16-05-1990
			JP 57082322 A	22-05-1982
			PT 73706 A	01-10-1981
			US 4596709 A	24-06-1986
			ZA 8106463 A	29-09-1982
US 2004072791	A1	15-04-2004	AU 3318902 A	03-06-2002
			CA 2428473 A1	30-05-2002
			DE 10057976 A1	29-05-2002
			WO 0242484 A2	30-05-2002
			EP 1373543 A2	02-01-2004
			JP 2004519220 T	02-07-2004
FR 2781673	A	04-02-2000	NONE	
WO 0160378	A	23-08-2001	AU 4644101 A	27-08-2001
			BR 0108354 A	11-03-2003
			CA 2400244 A1	23-08-2001
			CN 1404395 A	19-03-2003
			CZ 20022702 A3	15-01-2003
			DE 10006989 A1	23-08-2001
			EP 1267891 A2	02-01-2003
			HU 0300409 A2	28-06-2003
			JP 2003522796 T	29-07-2003

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

## EP 1 721 611 A1

ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.

EP 05 10 3260

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-09-2005

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0160378 A		MX PA02007970 A	29-11-2002
		NO 20023846 A	11-10-2002
		NZ 520642 A	30-04-2004
		PL 363272 A1	15-11-2004
		SK 11682002 A3	04-03-2003
		TR 200202008 T2	23-12-2002
		US 2003022863 A1	30-01-2003
		ZA 200206177 A	06-02-2003
-----			

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

## EP 1 721 611 A1

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- WO 0160378 A [0022] [0024] [0029]
- WO 0242484 A [0022]
- EP 1201137 A [0042]
- NL 2004000748 [0049]
- EP 05075486 A [0049] [0049]
- EP 0545946 A [0059]
- WO 02083164 A [0059]

## Non-patent literature cited in the description

- FULLER, R. J. *Applied Bacteriology*, 1989, vol. 66, 365-378 [0046]
- STACKEBRANDT ; GOEBEL. *Int. J. Syst. Bacteriol.*, 1994, vol. 44, 846-849 [0048]
- HENIKOFF ; HENIKOFF. *PNAS*, 1992, vol. 89, 915-919 [0048]
- GCG Wisconsin Package. Accelrys Inc, [0048]
- REMINGTON'S. *Pharmaceutical Sciences*. Mace Publishing Company, 1985 [0063]
- SAMBROOK ; RUSSELL. *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, 2001 [0076]
- AUSUBEL et al. *Current Protocols in Molecular Biology*, Current Protocols. 1994, vol. 1 and 2 [0076]
- REMINGTON'S. *Pharmaceutical Sciences*. Mack Publishing Company, 1985 [0076]
- JAMES CAPPUCCINO. *Microbiology: A Laboratory Manual* [0076]
- W. HARRIGAN. *Laboratory Methods in Food Microbiology*. Academic Press [0076]